Skip to content

The Oncology Institute, Inc. TOI Contract with Customer, Liability

Contract with Customer, Liability at other companies

Exelixis logo
ExelixisEXEL
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s contract with customer, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s contract with customer, liability?
The Oncology Institute, Inc. (TOI) reported contract with customer, liability of $0 in Q1 2026.
How has The Oncology Institute, Inc.'s contract with customer, liability changed year-over-year?
The Oncology Institute, Inc.'s contract with customer, liability decreased by 100.0% year-over-year, from $4.08M to $0.
What is the long-term trend for The Oncology Institute, Inc.'s contract with customer, liability?
Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s contract with customer, liability has grown at a -100.0% compound annual growth rate (CAGR), from $220K to $0.